Biodexa Pharmaceuticals (BDRX) Common Equity (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Common Equity data on file, last reported at $15.2 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 42.03% year-over-year to $15.2 million; the trailing twelve-month figure through Dec 2025 stood at $15.2 million (up 42.03% YoY), and the FY2025 full-year result was $15.0 million, up 40.78% from the prior year.
• Common Equity eased to $15.2 million in Q4 2025, from $15.3 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $15.3 million in Q2 2025 to a low of $3.7 million in Q4 2022.
• A 5-year average of $9.7 million and a median of $10.1 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity plunged 73.68% in 2022 and surged 83.97% in 2024, its largest moves.
• Tracing BDRX's Common Equity over 5 years: stood at $14.1 million in 2021, then sank by 73.68% to $3.7 million in 2022, then soared by 56.55% to $5.8 million in 2023, then soared by 83.97% to $10.7 million in 2024, then soared by 42.03% to $15.2 million in 2025.
• Business Quant data shows BDRX's Common Equity at $15.2 million in Q4 2025, $15.3 million in Q2 2025, and $10.7 million in Q4 2024.